Education
About Us
Working with TipRanks
Follow Us
Whitehawk Therapeutics (WHWK)
NASDAQ:WHWK
Total Valuation
Whitehawk Therapeutics has a market cap or net worth of $80.70M. The enterprise value is $39.06M.
Market Cap$80.70M
Enterprise Value$39.06M
Share Statistics
Whitehawk Therapeutics has 46,784,620 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,784,620
Owned by Insiders26.48%
Owned by Institutions26.46%
Financial Efficiency
Whitehawk Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee―
Profits Per Employee―
Employee Count40
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Whitehawk Therapeutics is ―. Whitehawk Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Whitehawk Therapeutics had revenue of ― and earned ― in profits. Earnings per share was ―.
Revenue―
Gross Profit―
Operating Income―
Pretax Income―
Net Income―
EBITDA―
Earnings Per Share (EPS)―
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Whitehawk Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.42
52-Week Price Change-14.00%
50-Day Moving Average1.90
200-Day Moving Average2.13
Relative Strength Index (RSI)52.80
Average Volume (3m)143.99K
Important Dates
Whitehawk Therapeutics upcoming earnings date is May 7, 2025, TBA Not Confirmed.
Last Earnings DateMar 19, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Whitehawk Therapeutics as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Whitehawk Therapeutics has paid ― in taxes.
Income Tax―
Effective Tax Rate―
Enterprise Valuation
Whitehawk Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Whitehawk Therapeutics has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt―
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Whitehawk Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast6.69%
EPS Growth Forecast3.57%